Intravitreal aflibercept 8 mg could improve treatment outcomes and provide sustained disease control in patients with neovascular age-related macular degeneration (nAMD), with extended dosing compared with aflibercept 2 mg. ⋯ Bayer AG and Regeneron Pharmaceuticals.
read on…
or not…